Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Eur J Pharmacol
2014 Jun 05;732:159-68. doi: 10.1016/j.ejphar.2012.06.001.
Show Gene links
Show Anatomy links
Allosteric modulation of alpha4beta2 nicotinic acetylcholine receptors by HEPES.
Weltzin MM
,
Huang Y
,
Schulte MK
.
???displayArticle.abstract???
A number of new positive allosteric modulators (PAMs) have been reported that enhance responses of neuronal alpha7 and alpha4beta2 nicotinic acetylcholine receptor subtypes to orthosteric ligands. PAMs represent promising new leads for the development of therapeutic agents for disorders involving alterations in nicotinic neurotransmission including Autism, Alzheimer's and Parkinson's disease. During our recent studies of alpha4beta2 PAMs, we identified a novel effect of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES). The effects of HEPES were evaluated in a phosphate buffered recording solution using two-electrode voltage clamp techniques and alpha4beta2 and alpha7 nicotinic acetylcholine receptor subtypes expressed in Xenopus laevis oocytes. Acetylcholine induced responses of high-sensitivity alpha4beta2 receptors were potentiated 190% by co-exposure to HEPES. Responses were inhibited at higher concentrations (bell-shaped concentration/response curve). Coincidentally, at concentrations of HEPES typically used in oocyte recording (5-10mM), the potentiating effects of HEPES are matched by its inhibitory effects, thus producing no net effect. Mutagenesis results suggest HEPES potentiates the high-sensitivity stoichiometry of the alpha4beta2 receptors through action at the beta2+/beta2- interface and is dependent on residue beta2D218. HEPES did not potentiate low-sensitivity alpha4beta2 receptors and did not produce any observable effect on acetylcholine induced responses on alpha7 nicotinic acetylcholine receptors.
Adams,
Evidence for a role of nicotinic acetylcholine receptors in schizophrenia.
2007, Pubmed
Adams,
Evidence for a role of nicotinic acetylcholine receptors in schizophrenia.
2007,
Pubmed
Aubert,
Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases.
1992,
Pubmed
Bertrand,
Allosteric modulation of nicotinic acetylcholine receptors.
2007,
Pubmed
Brejc,
Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors.
2001,
Pubmed
Butt,
Bovine serum albumin enhances nicotinic acetylcholine receptor function in mouse thalamic synaptosomes.
2002,
Pubmed
Court,
Nicotinic receptor abnormalities in Alzheimer's disease.
2001,
Pubmed
Desmarais,
The 1.20 A resolution crystal structure of the aminopeptidase from Aeromonas proteolytica complexed with tris: a tale of buffer inhibition.
2002,
Pubmed
García,
GABA released from cultured cortical neurons influences the modulation of t-[(35)S]butylbicyclophosphorothionate binding at the GABAA receptor Effects of thymol.
2008,
Pubmed
Ghalanbor,
Binding of Tris to Bacillus licheniformis alpha-amylase can affect its starch hydrolysis activity.
2008,
Pubmed
Good,
Hydrogen ion buffers for biological research.
1966,
Pubmed
Gotti,
Partial deletion of the nicotinic cholinergic receptor alpha 4 or beta 2 subunit genes changes the acetylcholine sensitivity of receptor-mediated 86Rb+ efflux in cortex and thalamus and alters relative expression of alpha 4 and beta 2 subunits.
2008,
Pubmed
Gäb,
Stable adducts of nerve agents sarin, soman and cyclosarin with TRIS, TES and related buffer compounds--characterization by LC-ESI-MS/MS and NMR and implications for analytical chemistry.
2010,
Pubmed
Harvey,
Identification of an inhibitory Zn2+ binding site on the human glycine receptor alpha1 subunit.
1999,
Pubmed
Hsiao,
Subunit-dependent modulation of neuronal nicotinic receptors by zinc.
2001,
Pubmed
,
Xenbase
Joshi,
A vertical flow chamber for Xenopus oocyte electrophysiology and automated drug screening.
2004,
Pubmed
,
Xenbase
Kasai,
A comment on the analysis of bell-shaped dose-response curves.
1998,
Pubmed
Kim,
Synthesis of desformylflustrabromine and its evaluation as an alpha4beta2 and alpha7 nACh receptor modulator.
2007,
Pubmed
,
Xenbase
Levin,
Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.
2007,
Pubmed
Li,
Voltage-dependent transient currents of human and rat 5-HT transporters (SERT) are blocked by HEPES and ion channel ligands.
2002,
Pubmed
,
Xenbase
Liu,
Agonist-induced hump current production in heterologously-expressed human alpha4beta2-nicotinic acetylcholine receptors.
2008,
Pubmed
Luo,
Effect of HEPES buffer on the uptake and transport of P-glycoprotein substrates and large neutral amino acids.
2010,
Pubmed
Marks,
Nicotinic-agonist stimulated (86)Rb(+) efflux and [(3)H]epibatidine binding of mice differing in beta2 genotype.
2000,
Pubmed
Martin-Ruiz,
Molecular analysis of nicotinic receptor expression in autism.
2004,
Pubmed
Moroni,
Non-agonist-binding subunit interfaces confer distinct functional signatures to the alternate stoichiometries of the alpha4beta2 nicotinic receptor: an alpha4-alpha4 interface is required for Zn2+ potentiation.
2008,
Pubmed
,
Xenbase
Moroni,
alpha4beta2 nicotinic receptors with high and low acetylcholine sensitivity: pharmacology, stoichiometry, and sensitivity to long-term exposure to nicotine.
2006,
Pubmed
,
Xenbase
Moroni,
Stoichiometry and pharmacology of two human alpha4beta2 nicotinic receptor types.
2006,
Pubmed
,
Xenbase
Nelson,
Alternate stoichiometries of alpha4beta2 nicotinic acetylcholine receptors.
2003,
Pubmed
,
Xenbase
Nury,
X-ray structures of general anaesthetics bound to a pentameric ligand-gated ion channel.
2011,
Pubmed
Pandya,
Allosteric modulator Desformylflustrabromine relieves the inhibition of α2β2 and α4β2 nicotinic acetylcholine receptors by β-amyloid(1-42) peptide.
2011,
Pubmed
,
Xenbase
Pavlovicz,
Identification of a negative allosteric site on human α4β2 and α3β4 neuronal nicotinic acetylcholine receptors.
2011,
Pubmed
Picciotto,
Neuronal nicotinic acetylcholine receptor subunit knockout mice: physiological and behavioral phenotypes and possible clinical implications.
2001,
Pubmed
Poole,
The adverse effects of HEPES, TES, and BES zwitterion buffers on the ultrastructure of cultured chick embryo epiphyseal chondrocytes.
1982,
Pubmed
Sala,
Potentiation of human alpha4beta2 neuronal nicotinic receptors by a Flustra foliacea metabolite.
2005,
Pubmed
,
Xenbase
Smulders,
Cholinergic drugs potentiate human nicotinic alpha4beta2 acetylcholine receptors by a competitive mechanism.
2005,
Pubmed
,
Xenbase
Taly,
Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system.
2009,
Pubmed
Tapia,
Ca2+ permeability of the (alpha4)3(beta2)2 stoichiometry greatly exceeds that of (alpha4)2(beta2)3 human acetylcholine receptors.
2007,
Pubmed
,
Xenbase
Weltzin,
Pharmacological characterization of the allosteric modulator desformylflustrabromine and its interaction with alpha4beta2 neuronal nicotinic acetylcholine receptor orthosteric ligands.
2010,
Pubmed
,
Xenbase
Wonnacott,
Presynaptic nicotinic ACh receptors.
1997,
Pubmed
Yamamoto,
Blockage of chloride channels by HEPES buffer.
1987,
Pubmed
Zwart,
Four pharmacologically distinct subtypes of alpha4beta2 nicotinic acetylcholine receptor expressed in Xenopus laevis oocytes.
1998,
Pubmed
,
Xenbase
